Oral hypoglycemics are involved in the current treatment therapy for type II diabetes mellitus. Continuous research on developing an improved class of oral hypoglycemic led to the development of SGLT2 inhibitors. Their unique mechanism of action made them most sought after the class of oral hypoglycemic. Various clinical studies have disclosed that SGLT2 inhibitors are devoid of many side effects compared to other classes of oral hypoglycemics. Discovery of these inhibitors began with the extensive studies on phlorizin, which provide the basic architecture for all the other glifozins i.e. SGLT2 inhibitors. Many molecules of this class such as dapagliflozin, canagliflozin, empagliflozin have been approved by USFDA for the treatment of type II diabetes mellitus. This work provides all the disclosed details of approved gliflozins and other gliflozins which are in development phase, in the conquest of finding "fool-proof" gliflozin.
Background
Diabetes continues to be a serious illness, frequently observed among the people of developed nations around the world. As per estimation by WHO, till the year 2014, 400 million people have suffered from diabetes and there are approximately 2.2 million deaths per year due to diabetes. The highest mortality rate is reported in the patients of age group below 70 years in high income countries. In US, diabetes is the seventh foremost cause of deaths (1) . Diabetes mellitus is basically an endocrine disorder which is characterized by an increase in the glucose level in the blood. This disorder occurs either due to insulin impairment or flaw in insulin secretion or combination of both. The other risk factors due to diabetes include obesity, overweight, physical immobility etc. This further leads to lot of other complications like hyperglycemia, interruption in the fat, protein and carbohydrate metabolism, retinopathy, neuropathy, nephropathy and heart related problems. The hyperglycemia leads to symptoms like polyuria, polydypsia, weight loss. Thus diabetes can be considered as a heterogeneous disease (2) .
Diabetes mellitus can be classified into two major subtypes; Type 1 diabetes, also called insulin dependent diabetes mellitus (IDDM) and Type 2 diabetes, also known as non-insulin independent diabetes mellitus (NIDDM). In Type 1 diabetes, there is damage of pancreatic β cells, and so pancreas is unable to produce enough insulin and thus results in deficiency of insulin. On the other hand, Type 2 diabetes is the most common form of diabetes and indicates defect in the insulin secretion and insulin resistance (3) .
Earlier treatment of diabetes involved administration of subcutaneous injections of insulin. But with the improved knowledge of subtypes of diabetes and molecular pathways involved in them, the treatment regime of diabetes has taken a paradigm shift. Nowadays, a variety of oral hypoglycemic agents including sulphonylureas, meglitinides, biguanides, alpha glucosidase inhibitors and thiazolidenediones have been developed for the treatment of diabetes mellitus (4) . The basic motive of these agents is to specifically treat the patients and correct the underlying implications observed in them. Thus, the various side effects associated with already approved drugs imply the discovery and development of other novel, safer and more potent antidiabetic drugs with less toxic effects (5) .
port sodium into the cell in exchange of glucose or several other molecules by active transport i.e. against the concentration gradient across the basolateral surface of the cell (6) . The two main isoforms of SGLT include SGLT1 and SGLT2 and mediates the renal glucose reabsorption process. SGLT1 absorbs glucose from the small intestine whereas SGLT 2 is responsible for the reabsorption of glucose filtered by the kidney. Around 90% of the filtered glucose is reabsorbed by the SGLT2 and the remaining is reabsorbed by SGLT1. The SGLT2 has high capacity, low-affinity transporter and mainly present in the S1 segment of kidney. SGLT1 is located in the S2 and S3 segment of proximal convoluted tubule and characterized by low capacity and high affinity (7). SGLT2 inhibitors have been developed upon the impression that SGLT2 provide a better target for the treatment of type 2 diabetes mellitus. These drugs act by blocking the reabsorption of filtered glucose in the proximal tubule, thus, lowering the increased glucose level in blood hyperglycemia) by eliminating significant amount of glucose through urine glucosuria) and this provides a new insulin independent approach (8) . In this review, our focus is on structural features, synthetic strategy, mechanism of action and biological data related to the various discovered, US-FDA approved and under clinical trial SGLT2 inhibitors in the treatment of diabetes.
Oral Hypoglycemic Agents

Biguanides
Initially, in 1957, two drugs of the class biguanides, metformin and phenformin, were introduced as oral hypoglycemic. They were used to treat non-insulin-dependent diabetes mellitus. Biguanides basically consist of a two guanidine moieties merged together. The hypoglycemic activity of biguanides was first reported as early as in the year 1918 (9) . Following continuous research studies, in 1957 metformin and phenformin were reported to possess significant hypoglycemic activity (10) . Later on, due to severe adverse effects such as lactic acidosis, phenformin has been withdrawn from most of the countries. However, metformin continues to represent its class, biguanides, among diabetic treatment therapies. Metformin, structurally, is a dimethyl derivative of bi-guanidine (two fused guanidine units). Metformin, rather than being hypoglycemic, is reported as anti-hyperglycemic in function. The overdose of metformin does not reduce the glucose levels below the normal level (11) . The mechanism of action of metformin involves insulin-mediated glucose disposal. This claim was supported by the fact that metformin does suddenly increase the insulin level in the blood and further improvement in glucose tolerance was observed independent of increase in insulin concentrations (12) . However, many side effects such as diarrhea, abdominal discomfort, nausea, anorexia, etc, was observed in case of metformin administration, which point out to the fact that there is need of newer drug discovery for diabetes treatment therapies (13).
Sulphonyl Ureas
Sulphonyl ureas are another class of oral hypoglycemic, consisting of amide based molecules. This class is majorly classified into: first generation agents and second generation agents. First generation sulphonyl ureas consist of drugs like acetohexamide, chlorpropamide, tolazamide and tolbutamide, while the second generation agents include drugs such as glimepiride, glipizide and glyburide. The second generation sulphonyl ureas were discovered to improve the potency and safety of the previously approved sulphonyl ureas. Structurally, sulphonyl ureas class of drugs contain a central S-aryl sulfonylurea moiety with a p-substituted phenyl ring and other substitutions at the urea moiety (14) . Drugs of sulphonyl ureas class, act by stimulating pancreatic β cells which in turn release more insulin by blocking ATP sensitive potassium channels in β cells. The released insulin thus, reduce glucose concentrations in the blood (15).
Meglitinides (Glinides)
Non-sulphonylureas like meglitinide, nateglinide, repaglinide were reported for the first time as oral hypoglycemics. They pertain to similar mechanism of action as that of sulphonyl ureas, however vary in the pharmacokinetic parameters like meglitinide have short half life than that of sulphonyl ureas. Commonly observed side effects in case of nonsulphonylureas include headache, dizziness, respiratory problems and sometimes hypoglycemic conditions etc. (16).
Thiazolidinediones
In 1982, with the discovery of Ciglitazone, another class of hypoglycemics came to limelight, thiazolidinediones (TZDs) derivatives. Ciglitazone was an orally active drug, targeting one of the major cause of disease i.e. insulin resistance. Further, numerous of drugs belonging to this was approved including pioglitazone, troglitazone, rosiglitazone, englitazone, which share a common structural feature i.e., thiazolidine-2-4-dione nucleus, as present in ciglitazone (17) . Among these drugs, troglitazone was the first approved drug in US, which came after rosiglitazone and pioglitazone. The exact mechanism of thiazolidinediones drugs has not been identified. However, it has been reported that, drugs act via binding with PPARγ (peroxisome 2 J Biomed. 2016; 1(4):e10052.
proliferator activated receptor gamma) receptor, present in insulin sensitive tissues like in adipocytes. Activation of the receptor change the insulinresponsive gene expression, thus alter the differentiation of adipocytes and metabolism of glucose and lipid (18) . Though many side effects related to TZDs are fluid retention, weight gain, and risk of heart failure etc (19) .
Alpha-Glucosidase Inhibitors (AGIs)
Acarbose, a FDA approved drug in 1995, was reported to be used as a mono therapy in non-insulin dependent diabetes mellitus patient (20) . It was the competitive, reversible alpha-glucosidase inhibitor. Acarbose acts by inhibiting the alpha-glucosidase enzymes present in small intestines and thus lower the absorption of glucose from the intestine. It is an optional drug of choice in lowering blood glucose level in people in contrast to other oral hypoglycemic drugs as mentioned above. Other alphaglucosidase inhibitor drugs are miglitol and voglibose. These drugs act by targeting after meal hyperglycemia. AGIs drugs are mainly valuable in combination with other drugs (21). However, major side effects of AGIs are GIT problems, swelling in abdomen, diarrohea, flatulence and pain (22) .
Dipeptidyl Peptidase-4 (DPP-4) inhibitors
Dipeptidyl peptidase-4 (DPP-4) inhibitors or Gliptins like sitagliptin (approved by FDA in 2006) and vildagliptin are new class of antidiabetic drugs for the treatment of type 2 diabetes (23). DPP-4 inhibitors act by increasing the incretin level (glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP). Thus, in turn, stimulates the insulin secretion, inhibits glucagon secretion and lowered the blood glucose level (24) . During the clinical trials, it has been observed that 100 mg dose of sitagliptin once in a day is efficacious monotreatment for type 2 diabetes. Sitagliptin is also used in combination with metformin or pioglitazone. Similarly, vildagliptin showed good efficacy at dose of 100 mg but it is less active in comparison with metformin (25) . Adverse effects of DPP-4 inhibitors include GIT problems, diarrohea, headache, angioedema, skin problems like rhinitis and urticaria etc (26).
Sodium Glucose Co Transporter (SGLT2) Inhibitors
SGLT2 inhibitors act by inhibiting renal glucose reabsorption and are reported to prevent the reabsorption of approx. 70 g of glucose per day (27) . Basically, this class of inhibitors contains two structural subunits, first unit is the glycone moiety and second is the synthetic moiety and these are fused together via C-aryl linkage. Initial molecules of this class such as T1095, sergliflozin, and remogliflozin, had O-glycosidic linkage between the two subunits and thus, even though few of them were very potent. They were found susceptible to the intestinal glycosidases, which led to their degradation and these molecules could not progress to the clinical trials (28) . Later on, development of the molecules of this class was based upon the replacement of O-glycosidic linkage with the C-aryl linkage. Thus, making them stable against intestinal glycosidases enzymes (29).
Phlorizin and Its Derivatives
Phlorizin is a naturally occurring phenolic glycoside which was first isolated from apple tree bark in 1835 and was reported to increase urinary excretion of glucose and lowered blood glucose (30) . Initially, the glucosuric effect of phlorizin was interpreted as suggestive of cause of diabetes. Later on, in the 1990s, phlorizin was reported as an inhibitor of both of SGLT1 and SGLT2 transporters. But as the oral bioavailability of phlorizin was not up to the mark due to the degradation at an O-glucoside linkage by intestinal glucosidases, it was excluded from drugs used in the treatment for patients with type 2 diabetes. Structurally, phlorizin is the biphenolic aglycone moiety attached to glycone moiety containing compound. It is a natural SGLTs specific inhibitor, provided proof of concept in vivo by promoting glucose excretion and lowering fasting and postprandial blood glucose level without hypoglycemic -side effects in several animal models (31) . Later on, Dudash et al. reported various phlorizin derived molecules, illustrated in Figure 1 . Many of such molecules were found to possess significant potent SGLTs, specially against SGLT2 but none of them could make it to clinical trial (32).
FDA Approved Gliflozins
Dapagliflozin
Dapagliflozin is one of the C-aryl glycosidic, FDA approved SGLT2 inhibitor in year 2012 in Europe and approved in USA in 2014 (32) . Reported in 2008, it is competitive, reversible, and highly selective inhibitor of SGLT2 (29) . Structurally, dapagliflozin consist of biaryl synthetic subunit attached with the glycon moiety. Dapagliflozin acts by blocking SGLT2 and reduces the reabsorption of glucose into the blood. It enhances the glucose filtration through the kidneys and into the urine to be omitted from the body and as it does not directly involve the suppression of release of insulin, the side effects such as hypoglycemia, are rarely observed in patients (33) . During clinical studies, it was also observed that doses between 20 -100 mg of dapagliflozin resulted in urinary glucose excretion of about 50 -60 g over the time period of 24 hours in healthy volunteers (34) . 10 mg dose of dapagliflozin once in a day assures both efficacy and safety among other antidiabetic agents as monotreatment. The drug is also given in combination with metformin, sulphonyl urea, and metformin, sulphonyl urea and pioglitazone (35) .
In general, the synthesis of dapagliflozin consist of 6 steps, start with the treatment of 5 with TMSCl (Trimethylsilyl chloride) and NMM (N-Methylmorpholine) in tetrahydrofuran at temperature of 35°C to yield 6. Simultaneously, 7 is treated with chloroformyl chloride and phenetole in presence of AlCl 3 using DCM and DMF to afford 8. Further, reduction of 8 was performed using triethylsilane and BF 3 OEt 2 which afforded 9. Finally, 9 was subjected to lithium halogen exchange, peracetylation and hydrolysis with lithium hydroxide to yield desired product dapagliflozin (29) . SAR study disclosed that substitutions on ring A and B are crucial for inhibitory activity, any alteration led to reduction in potency (Figure 2 ). Few research groups have performed studies reporting substitutions on glycone moiety leading to improvement in activity (36).
Canagliflozin
Canagliflozin is another oral SGLT2 inhibitor or C-aryl glycoside approved by US-FDA in 2013 (7) . It consists of a thiophene-based synthetic subunit attached with the sugar moiety (37) . Chemically, canagliflozin is termed as (2S,3R,4R,5S,6R)-2-(3-(5-(4fluoro-phenyl)-thiophen-2-ylmethyl)-4-methyl-phenyl-6-hydroxy-methyltetrahydropyran 3,4,5 triol (37, 38) .
Similar to dapagliflozin, canagliflozin controls glycemic concentration through an insulin-independent approach, via inhibition of SGLT2 within the kidney (39) . During clinical studies, with the doses of 100 mg daily and 300 mg twice daily doses, there was no significant malabsorption of glucose was observed. Oral administration of 300 mg canagliflozin in healthy subjects resulted in delayed plasma appearance of orally ingested glucose as compared to the placebo (40) . Other clinical study revealed the fact that canagliflozin showed improved results on parameters such as, HbA1c, FPG, PPG, and weight, which are comparable with those observed in case of dapagliflozin (41) .
Synthesis of canagliflozin involve reaction of 10 with nbutyllithium in THF to give 11, followed by treatment of 11 with zinc bromide and lithium bromide at room temperature to yield 12, which was further coupled with glycone moiety by treating with glycosyl bromide affording 13. It was subjected to sodium methoxide in methanol to obtain desired product (42) . In addition, SAR study revealed that presence of halogen or lower alkyl groups as a substituent on ring A in place of proton resulted in improved in vitro potency (Figure 3) . Also, aryl substituent in comparison to alkyl or halogen on ring B enhanced in vivo potency and chemical stability (37) .
Empagliflozin
Empagliflozin, is another potent, competitive and highly selective SGLT2 inhibitor, recently approved by FDA in 2014, used for the treatment of type 2 diabetes. Chemically, it is C-glucoside based structure containing a tetrahydrofuran substitution on the second ring of the synthetic sub-unit and named as 1-chloro-4-(β-D-glucopyranos-1yl)-2-(4-((S)-tetrahydrofuran-3-yl-oxy)-benzyl)-benzene (43) . Similar to other gliflozins, empagliflozins act by inhibiting SGLT 2 cotransporter, through an insulin independent approach. Thus, decrease in absorption of glucose from kidney and increase in the urinary glucose excretion. Empagliflozins can be given as monotherapy or in combination with other drugs to reduce glucose level. During clinical study, it has been found that 10 mg and 25 mg dose of drug once in a day is able to improve the glycemic control (44) . However, the common side effects associated with empagliflozins are UTI (urinary tract infection) and Synthesis of empagliflozin ( Figure 4 ) involves selective oxidation of 14, in the presence of cyclohexanone as a co-oxidant, in DMF to give 15. Hydroxyl groups of 15 are then protected using trimethylsilyl chloride, in presence of NMM using THF to yield 16. Simultaneously, 17 is lithiated and treated with 16 to give 18, followed by treatment with methanesulfonic acid in methanol resulting the formation of 19 and further reduction of 19 using Et 3 SiH and BF 3 OEt 2 , afforded the desired product (46) . SAR study of empagliflozin highlighted the significance of tetrahydrofuran moiety on the second aryl ring of the molecule, which improved its efficacy compare to other counterparts.
Other Gliflozins Which Are Under Clinical Trial 3.3.1. Ipragliflozin
In 2012, Imamura et al., reported the synthesis of a heteroaryl C-glycosidic based molecule, ipragliflozin, as a novel SGLT2 inhibitor as shown in Figure 5 . Ipragliflozin contains benzothiophene based synthetic subunit attached with the glycon moiety (47) . Similar to other gliflozins, ipragliflozin also act by inhibiting SGLT2, which is responsible for the majority of renal glucose reabsorption. In-vitro SGLT inhibitory assay of ipragliflozin, which involved monitoring of the inhibition of accumulated AMG in Chinese hamster ovary cells expressing human SGLT2 or SGLT1, showed significant IC 50 value of 9.8 nM. Further, the cell line result complied with the KK-Ay mice and STZ rats diabetic models as ipragliflozin reduced blood glucose levels in a dose-dependent manner. Further, SAR study of the molecule showed that the hydroxyl group at the ortho position to the glycoside of the benzene ring was responsible for the effective inhibitory activity (47) .
Synthetic scheme ( Figure 5 ) involve treatment of 20 with butyl lithium alongwith addition of a Grignard reagent to an aldehyde, followed, by reduction of the re- In subsequent steps, 21 was subjected to butyl lithium, followed by lithium halogen exchange and then addition of a lithiated 21 to gluconolactone afforded lactol, which was reduced by treatment with Et 3 SiH and BF 3 (OEt) 2 to give 22. Finally, removal of the benzyl groups from 22 using BCl 3 , generated desired product. SAR study disclosed that substitution of hydroxyl or methoxy at the ortho position to the glycoside of the benzene ring effectively increase inhibitory activity. The introduction of a chlorine atom led to a three-fold decrease. Similarly, hydroxyl or methoxy group substitutions at the para position to the glycoside of the benzene ring resulted in a poor selectivity towards SGLT1 (47).
Tofogliflozin
In 2012, Chugai Pharmaceuticals disclosed a potent, selective and O-spiroketal, C-aryl glucoside SGLT2 inhibitor known as tofogliflozin. However, the drug is still in phase III of clinical trials. In Japan, in 2014, it got first global approval both as monotherapy and or in combination with other antihyperglcaemic agents for type 2 diabetic patients (48) . Like other gliflozins, tofogliflozin reduce high glucose concentrations in blood by promoting excretion of glucose in urine by the selective inhibition of SGLT2 enzyme. Structurally, tofogliflozin has a presence of unique spiroketal ring which restricts the conformations of the molecule and thus limit the flexibility of its conformation. Pharmacodynamics data disclosed the fact that tofogliflozin have IC 50 value of 2.9 nmol/L against human SGLT2 and inhibitory constant (Ki) values were found to be 2.9, 14.9, and 6.4 nM, respectively for human, rat, and mouse SGLT2 inhibition (49) . Pharmacokinetic parameters of tofogliflozin were also reported and clearance and volume of distribution at steady-state (Vss) were found to be 10.0 ± 1.3 and 50.6 ± 6.7 l respectively (50). However, the major side effects include hyperketonemia (elevated ketone bodies level), ketonuria and pollakiuria.
Synthetic scheme ( Figure 6 ) starts with the reduction of two carboxyl groups of 23 to give 24, followed by protection of two hydroxyl groups with triphenylmethyl to yield 25, which was further treated with sec-butyllithium. Deprotection followed by spirocyclization afforded 26. Further oxidation was done which yielded aldehyde, followed by the treatment with lithiated benzenes resulted in formation of 27. Finally, the reductive cleavage of 27 afforded the desired product. SAR study disclosed the fact that the ethyl substitution was more potent and had higher SGLT2 selectivit y versus SGLT1. Interestingly, introduction of a chloro, methyl, or ethynyl group at ring A slightly increased the SGLT2 inhibitory potential but significantly reduced the SGLT2 selectivity over SGLT1 (51).
Sergliflozin
In 2007, Katsuno et al. reported the evaluation of sergliflozin as a SGLT2 inhibitor. Currently, sergliflozin is in phase II of the clinical trial. Structurally, it is a benzylphenol based O-glucoside SGLT2 inhibitor glucoside. Interestingly, during study, sergliflozin was found to act as a prodrug and its active form sergliflozin-A behaved as a potent SGLT2 inhibitor (52) . Further study also reported that sergliflozin-A was approximately several times more active against SGLT2 compared to phlorizin. Moreover, it was also reported that it has no influence on GLUT 1 activity, thus reducing the side effects commonly observed in case of other SGLT2 inhibit ors. During its clinical study, it has been observed that sergliflozin reduce after meal glucose level in diabetic rats by inducing glucose excretion, independent of insulin secretion. The inhibitor constant (Ki) values for human SGLT2 shown by sergliflozin A and sergliflozin were 2.39 ± 0.35 and 151 ± 17 respectively (53).
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J Biomed. 2016; 1(4):e10052. Synthesis of sergliflozin ( Figure 7 ) involves protection of hydroxyl groups of 28 to give 29, which is further reduced to yield 30. Further, treatment with mesyl chloride and trimethylamine in DCM result in 31 which on coupling with Baylis-Hillman product of p-methoxybenzaldehyde and cyclohexanone give 32. Finally, treatment of 32 with the combination of (Pd(dba)2) and dppe afforded the desired product. SAR study of the compound disclosed that the C-6 hydroxy group of sugar was very important for SGLT2/SGLT1 selectivity. The β-stereogenic configuration at C-5 and C-1 of the sugar moiety was found to be the key to the low-nanomolar SGLT2 inhibition (54).
YM543
In 2013, Ikegai et al., reported the discovery of potent SGLT2 inhibitor, YM543, for the treatment of type 2 diabetes mellitus. They explored the synthesis and structure activit y relationship of azulene derived C-glucoside SGLT2 inhibitors. Structural modification of the azulene moiety and incorporation of a phenolic hydroxyl group at the central benzene ring resulted in the more potent SGLT2 inhibitor, YM543. In vivo pharmacological profiling of YM543 revealed that a single oral dose of 0.1 -3.0 mg/kg resulted in a dose-dependent and sustained increase in urinary glucose excretion (UGE) that lasted over 12 hours at doses of 0.3 mg/kg or higher. Further, upon oral administration, this molecule was observed to be a strong and sustained antihyperglycemic against both KK/Ay type 2 diabetic mice and STZ type 1 diabetic rats (55) .
Synthesis of YM543 (Figure 8 ) involves treatment of 33 with butyl lithium in THF and coupling with β-C-glucoside to yield 34, which was reduced to afford 35. Further, 35 is selectively brominated using NBS to give 36, which, followed by deprotection, saponification and decarboxylation in the presence of para toluene sulphonic acid, afforded the desired product. SAR study exposed the fact that incorporation of alkyl and acetyl substituents at the 1-position of azulene leads to dramatic loss of SGLT2 inhibitory activity. Also, Azulen-2-yl derivatives are much more potent and selective than azulen-6-yl derivatives (55).
Ertugliflozin
In 2011, Mascitti et al., reported the discovery of ertugliflozin (PF-04971729), a new class of potent and selective sodium-dependent glucose cotransporter 2 inhibitor, containing a unique dioxa-bicyclo-(3.2.1) octane (bridged ketal) ring system. It is currently in phase 2 clinical trial and is being evaluated for the treatment of type 2 diabetes. This molecule was actually designed on the basis of a pharmacokinetic-pharmacodynamics (PKPD) relationship model. The designing strategy was aimed at reducing the parameters such as human dose through increasing t1/2 (via reducing the clearance of drug) and improving the potency. Thus, for ertugliflozin, the SGLT2 PKPD model predicted the human plasma clearance to be 1.7 mL/min/kg, which in turn increased the predicted t 1/2 to 12 hours. Finally, the IC 50 of the molecule was predicted to be 1.4 nM (56) .
Synthesis of ertugliflozin ( Figure 9 ) starts with the reaction of 37 and 38 in presence of butyl lithium in THF, to afford 39. Further, 39 is utilized to produce diol, 40 using TBAF, further substitution at C-5 of the glycoside moiety was incorporated using formaldehyde and K 2 CO 3 , to give 41. In the next step, formation of the oxetane take place, which on further treatment afforded the desired product (57) . SAR study of the molecule disclosed the role of 8-membered ring system in the glycoside moiety, which improves the metabolic stability. Further, the ethoxy on the ring B of the synthetic moiety improves the potency of the molecule (58).
Remogliflozin
Remogliflozin is a selective inhibitor of renal SGLT2 that improves glucose control via enhanced urinary glucose excretion. Similar to sergliflozin, it is in development phase and under process by Kissei pharmaceutical corporation and GlaxoS mithKline. The structure of this molecule vary from that of phlorizin, T-1095 and sergliflozin as it is based on a benzylpyrazole glucoside (59) . Remogliflozin has been reported to have a selectivity ratio of 365:1 and is a highly selective inhibitor for human SGLT2. It is orally administered as remogliflozin etabonate, which upon metabolic activation gets converted to its active form, remogliflozin. Clinical study disclosed that oral administration of remogliflozin etabonate increased urinary glucose excretion in a dose-dependent manner in mice and rats. Further it is reported that it reduced the plasma glucose without stimulating insulin secretion and lowered plasma glucose levels during the oral glucose tolerance test in a dose-dependent manner (60) .
Synthesis of remogliflozin ( Figure 10 ) starts with the reaction of 42 with an activating agent i.e. methanesulfonyl chloride, triethylamine used as base and THF was used as a solvent to yield 43. 43 was further treated with 44 in presence of sodium hydride as a base and solvent such as THF and 1,2-dimethoxyethane (DME) to afford 45. In the next step, 45 was reacted with hydrazine in presence of solvent i.e. toluene to provide 46. 
Luseogliflozin
Luseogliflozin, an oral, second-generation SGLT2 inhibitor, was developed by Taisho pharmaceutical for the treatment of type 2 diabetes mellitus. Luseogliflozin is a potent inhibitor of SGLT2, having a reported IC 50 value of 2.26 nM. Chemically, it belongs to the class small molecules phenyl-ethers sulphides. Luseogliflozin is reported to dose-dependently increase the urinary glucose excretion and reduce the blood glucose levels. The drug has a 1650-fold greater selectivity for SGLT2 over SGLT1. During pharmacokinetic study, luseogliflozin exhibited dose proportional pharmacokinetics with no cumulative effect. Mean time to maximum plasma concentration ranged from 0.67 to 2.25 hours and mean plasma half-life ranged from 9.2 to 13.8. However, few adverse effects such as increased urinary frequency (2.8%), hypoglycemia (2.4%), increased urinary macroglobulin β2 levels (2.1%) were observed (62) .
Synthesis of luseogliflozin ( Figure 11 ) starts with the selective bromination of 50 using Fe in chloroform as catalyst to give 51. In the next step, 51 is treated with COCl2 to yield 52, which is further coupled with ethy phenyl ether using AlCl 3 to afford 53, which is then reduced to 54 using triethyl silane and BF3 in diethyl ether. 54 was then coupled with the glycone moiety using Mg and dibromoethane as a catalyst in THF to yield 55. Finally, deprotection of 55 afforded the desired product (63).
Sotagliflozin
LX4211 is an orally administered small molecule developed by Lexicon pharmaceuticals, Inc. (Princeton, NJ, USA), which acts as a dual SGLT1/SGLT2 inhibitor. Structurally, sotagliflozin is an L-xyloside based molecule, which is claimed to effective both in type I and II diabetes. This molecule was developed on the basis of results obtained from the study performed on genetically modified mice which disclosed the fact that partial inhibition of SGLT1 act as complementary target of SGLT2 inhibition to lower blood glucose. In vitro cell line study overexpressing human SGLT2 and SGLT1 established that sotagliflozin inhibits SGLT2 with an IC 50 of 1.8 nmol/L and SGLT1 with an IC 50 of 36 nmol/L, therefore, possess around 20-fold selectivity for SGLT2 over SGLT1. Sotagliflozin was also reported to have improved glucose homeostasis in KKAy mice, a rodent model of T2DM (64) .
Synthesis of sotagliflozin ( Figure 12 ) starts from the reaction of 56 with amide coupling to yield 57. Further, introduction of aryl moiety on amide derivative i.e. 57 in presence of Grignard reagent to afforded 58. In next step, 58 was acetylated and reacted with sodium borohydride and methyl sulphide to yield 59. Finally, 59 was deprotected and crystallized to afford desired product (65).
Henagliflozin
In April 2016, Jiangsu Hengrui Medicine reported the development of henagliflozin, which is a L-proline based inhibitor of a sodium-glucose cotransporter 2. Currently it is in phase 2 of the clinical trial for the treatment of type 2 diabetes. Henagliflozin provides a harmonizing therapy to metformin for patients due to its insulin-independent mechanism of action. Most of the information is still not disclosed as it is under privately owned patent (66) . But few pharmacokinetics study have performed which evaluated the potential pharmacokinetic drug-drug interaction between henagliflozin and metformin in healthy subjects. It was disclosed that co-administration of henagliflozin with metformin had no effect on henagliflozin. Mutually, coadministration of metformin with henagliflozin had no clinically significant on metformin, although there was an 11% increase in metformin Cmax. All monotherapies and combination therapy were well tolerated. Henagliflozin can be co-administered with metformin without dose adjustment of either drug (67) .
Synthesis of henagliflozin ( Figure 13 ) involves alkylation of 60 to give 61, which was coupled with 62 using AlCl 3 as a catalyst to afford 63. Further, 63 was reduced using sodium borohydride in THF to afford 64, which was completely reduced using triethylsiane and BF3 to give 65. In next step, glycone moiety was coupled with 65 to yield 66, which upon further treatment resulted in desired product (68).
Limitations of SGLT2 Inhibitors
Urinary and genital tract infections were the most commonly observed adverse effects in case of SGLT2 inhibitors. Clinical studies observed a slight increase in the rate of UTIs in case of dapagliflozin subjects. Interestingly, in majority of the cases, the incidence of UTI or genital tract infections showed no dependence on the dapagliflozin dose. Same results were also observed in the studies with Figure 13 . Synthesis of Henagliflozin canagliflozin but, all the cases of reported UTI and genital tract infections were resolved with simple treatment (69) . Another frequently tackled problem is of hypoglycemia in the subjects treated with SGLT2 inhibitors. Wilding et al., have reported an increase of more than two fold in all the hypoglycemic events during dapagliflozin and insulin administration in comparison to placebo and insulin, but with only 16 hypoglycemic episodes in a total of 71 participants (70) . Similarly, Strojek et al., reported a small, dose independent increase in hypoglycemia from dapagliflozin administration (71) . However, Nauck et al., reported that compared to glipizide,dapagliflozin produce a significantly low hypoglycemic events of all types, with an incidence rate of 3.4% compared to 39.7% (72) .
In 2015, Taylor et al. hypothesized the various biologically plausible mechanisms whereby drugs of this class can potentially increase the risk of developing diabetic ketoacidosis. Thus, suggested that research studies should also focus on this aspect of SGLT2 safety studies (73) . Other side effect of SGLT2 includes dehydration. Most important outcomes of this are mental disturbance and arterial hypotension with the risk of syncope. Loss of water also leads to loss of body weight. Body weight reductions were reported in clinical trials with dapagliflozin (74) . One prospective side effect of SGLT2 inhibitors which may prevent their use in near future was observed in clinical trials with dapagliflozin. The incidence of bladder cancers was higher in the pooled dapagliflozin arms than in the pooled placebo arms of all larger trials. However, the difference in bladder cancer incidence was not statistically significant because of the low absolute tumor count (75).
Conclusion
The SGLT2 inhibitors present a novel and most attractive class of drugs which provide effective control and regulation on diabetes in a safe and well-tolerated manner. Their unique non-insulin dependent mechanism of action (inhibition of renal glucose absorption), along with significant benefits on weight and blood pressure make them most sought-after choice for supplementary therapy to patients, which are not well-managed with other medications. Many of the drugs of this class have been approved by FDA while, few others which are still in trials, have shown encouraging result. A key question which still exists with this class of inhibitors is simultaneous inhibition of SGLT1, how much of its inhibition is useful or well tolerated is yet to be disclosed.
